Analysts at Benchmark started coverage on shares of Acasti Pharma (NASDAQ:ACST) in a report released on Friday. The firm set a “buy” rating and a $7.00 price target on the biopharmaceutical company’s stock.

Separately, ValuEngine raised Acasti Pharma from a “sell” rating to a “hold” rating in a research report on Monday, November 20th.

Shares of Acasti Pharma (NASDAQ ACST) opened at $1.01 on Friday. Acasti Pharma has a 12-month low of $0.84 and a 12-month high of $3.36. The stock has a market capitalization of $15.06, a price-to-earnings ratio of -1.28 and a beta of 1.49.

COPYRIGHT VIOLATION NOTICE: “Acasti Pharma (ACST) Coverage Initiated by Analysts at Benchmark” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at

Acasti Pharma Company Profile

Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG).

Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.